Management Team

Margaret McGlynn

Margaret (Margie) McGlynn is a biopharmaceutical executive with significant commercial leadership experience, who is now focused on developing new treatments and a patient support group for homocystinuria, a rare genetic disease that affected her family.   After receiving a dual degree in Pharmacy and MBA in Marketing, Margie spent 26 years at Merck where she served in leadership roles in marketing, new product development and managed care, last serving as President, Global Vaccines and Anti-Infectives. After leaving Merck, Margie then served for 4 years as President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), a Product Development Partnership which helps accelerate HIV vaccine development by bridging government and philanthropic funding with academic and industry vaccine research and development capabilities.

Margie is also the founder and President of the Hempling Foundation for Homocystinuria Research, which she established in 2009 to support research for new therapies to address homocystinuria, a rare genetic disease that led to an early death of 2 of her sisters. She is also working to help establish a U.S. and global patient support group for patients with homocystinuria.

Margie also serves on the boards of Air Products and Chemicals, Vertex Pharmaceuticals and Amicus Therapeutics.